Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors (IMMUNOPARP)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
This study concerns the creation of a biological collection (blood samples) in patients with Epithelial Ovarian Cancerin in order to describe the immune response with PARP inhibitors.
Condition or disease
Other: blood sample
The aim is to assess the impact of anti-PARP on peripheral immune populations and the amount of DNA circulating; to correlate these data with tumor infiltration, with the initial clinical characteristics and with the clinical course; compare the immunogenic effect of different anti-PARPs.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
cohorte 1 : patients with Mutated BRCA epithelial ovarian cancer - interviewed by Olaparib cohorte 2 : patients with Recurrent epithelial ovarian cancer - maintained with Niraparib or Olaparib
Epithelial Ovarian Cancer
Eligible for treatment by anti-PARP treatment with Olaparib or Niraparib
informed consent signed
Non Epithelial Ovarian Cancer
Current or previous use of an immunosuppressive drug 14 days before inclusion